Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer Group
Configuration
| Company | Price d* | Change d* | Volume, Avg. k, d* | Market Cap. d* | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding d* | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 13,653.97 | 873.48 | 212.71 | -28.40 | 40.75 | 0.00 | 5.9431 | -0.36 | -1.1290 | -24.7484 | -0.09 | -0.11 | 7.5623 | - - | ||
| Maximum | - - | - - | - - | 458,604.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.01 | 701.8537 | 6.70 | 3.0051 | 85.3485 | 0.15 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
| Reata Pharmaceuticals, Inc. RETA | 172.36 | 0.04 0.02% | 1,909 vs. 954 | 6,566.00 | 22.00 | 192.00 | -70.00 | -1,490.00 | 5.1200 | 5.4820 | 0.0000 | 0.9628 | 8.4849 | 2.2110 | 0.3840 | 2.8209 | 38.00 | ||
| Mirati Therapeutics, Inc. MRTX | 58.70 | -0.10 -0.17% | 20,956 vs. 1,778 | 4,117.00 | 16.00 | -161.00 | -143.00 | -2,976.00 | -2.4900 | -4.3716 | 0.0000 | 0.9129 | -9.8722 | -0.1711 | -0.1433 | 7.2541 | 70.00 | ||
| Sarepta Therapeutics, Inc. SRPT | 104.54 | -4.57 -4.19% | 1,434 vs. 845 | 9,985.00 | 413.00 | 36.00 | -284.00 | -4,410.00 | 0.3800 | 83.5325 | 0.0000 | 0.8777 | 0.0874 | 0.0376 | 0.0112 | 2.9737 | 95.00 | ||
| PTC Therapeutics, Inc. PTCT | 39.23 | -3.15 -7.43% | 1,008 vs. 693 | 3,025.00 | 210.00 | -91.00 | 6.00 | -3,375.00 | -1.2000 | -5.9705 | 0.0000 | 0.6846 | -0.4358 | 0.1024 | -0.0512 | 1.8854 | 77.00 | ||
| Apellis Pharmaceuticals, Inc. APLS | 26.27 | -1.79 -6.38% | 5,504 vs. 2,493 | 3,267.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
| Madrigal Pharmaceuticals, Inc. MDGL | 288.58 | -14.09 -4.66% | 934 vs. 358 | 6,294.00 | 0.00 | -147.00 | -149.00 | -1,483.00 | -7.3800 | -8.6674 | 0.0000 | 0.0000 | 0.0000 | -0.1734 | -0.1363 | 9.2623 | 21.00 | ||
| Akero Therapeutics, Inc. AKRO | 28.09 | -1.67 -5.61% | 1,079 vs. 524 | 1,960.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
| Krystal Biotech, Inc. KRYS | 170.74 | -6.65 -3.75% | 344 vs. 219 | 4,910.00 | 45.00 | 0.00 | 14.00 | -268.00 | 0.0300 | 1336.3467 | 0.0000 | 0.9465 | 0.0206 | 0.0012 | 0.0011 | 12.2870 | 28.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.